Drug Profile


Alternative Names: 249320; Anti-MAG monoclonal antibody - GlaxoSmithKline; anti-myelin associated glycoprotein monoclonal antibody - GlaxoSmithKline; GSK-249320

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Myelin-associated glycoprotein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS trauma; Stroke

Most Recent Events

  • 12 Jun 2013 GlaxoSmithKline initiates enrolment in a phase II trial for Stroke in USA & Canada (NCT01808261)
  • 09 Nov 2011 Phase-II clinical trials in Stroke in Czech Republic (IV)
  • 09 Nov 2011 Phase-II clinical trials in Stroke in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top